Skip to main content

First-line immune checkpoint inhibitors versus chemotherapy in delaying quality of life deterioration in advanced NSCLC: a systematic review and meta-analysis

In brief

First-line immune checkpoint regimens cut global quality-of-life deterioration by 25%

Across 15 randomized trials involving 7,127 people with advanced lung cancer, immune checkpoint inhibitor regimens were linked to a 25% lower rate of global quality-of-life deterioration than chemotherapy. The benefit was clear for regimens that also included chemotherapy, but not for immunotherapy without chemotherapy; whether quality-of-life changes track with survival remains uncertain.

Journal
BMC medicine (Q1)
Published
14 August 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Juanyan Shen, Junliang Ma, Shaolin Chen, Qisha Li, Su-Han Jin, Chi Zhang, et al.
PMID
43021226
DOI
10.1186/s12916-026-05127-w

Why clinicians should know about it

Abstract

BACKGROUD: Immune checkpoint inhibitors (ICIs) have reshaped first-line treatment for advanced non-small-cell lung cancer (aNSCLC). Overall survival (OS) remains central, but health-related quality of life (HRQoL) is increasingly important for patient-centered decision-making. Time to deterioration (TTD) captures the durability of HRQoL during treatment. We compared TTD outcomes between ICI-based therapies and chemotherapy(CT), and explored trial-level associations between hazard ratios (HRs) for TTD and OS. METHODS: PubMed, the Cochrane Library, and Scopus were searched from inception to September 2025. Eligible studies were phase II or III randomized clinical trials of first-line ICI-based therapy, including ICI monotherapy, dual ICI combinations, or ICIs plus CT, in patients with aNSCLC. Trials had to compare an ICI-based regimen with CT and report TTD for HRQoL. The prespecified primary outcome was the HR for TTD of global quality of life (QoL). Secondary outcomes were HRs for TTD of physical functioning, emotional functioning, and symptom domains. The protocol was registered with PROSPERO (CRD420251266405). RESULTS: A total of 7127 patients with aNSCLC from 15 randomized trials were included. Compared with CT, ICI-based therapies delayed deterioration of global QoL (HR, 0.75; 95% CI, 0.69-0.81; p < 0.001; I2 = 0%). Immunochemotherapy(ICT) delayed global QoL deterioration (HR, 0.73; 95% CI, 0.67-0.81; I2 = 0%), whereas ICI regimens without CT did not show a significant benefit (HR, 0.78; 95% CI, 0.58-1.05; I2 = 0%). ICI-based therapies also delayed deterioration in physical functioning, emotional functioning, and several symptom domains, including fatigue, pain, cough, dyspnea, hemoptysis, nausea and/or vomiting, and the composite of cough, chest pain, or dyspnea. No significant difference was observed for appetite loss. Exploratory trial-level analyses suggested positive associations between HRs for OS and HRs for TTD of emotional functioning and cough, although these findings were based on few comparisons. CONCLUSIONS: First-line ICI-based therapies, especially ICT, were associated with delayed HRQoL deterioration compared with CT. These findings support TTD as a clinically interpretable patient-reported endpoint that complements survival outcomes in aNSCLC trials. The trial-level association between HRQoL deterioration and OS should be interpreted cautiously and validated using individual patient data.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.